Newsroom | 9944 results

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported enco...

BELFAST, Ireland--(BUSINESS WIRE)--B-Secur launches ETS — a reference-based ECG test system giving wearable manufacturers an objective signal quality benchmark from bench to production....

SALT LAKE CITY--(BUSINESS WIRE)--Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR™) platforms for antibody and small molecule drug discovery, today announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery. The effort brings together scientific and technical expertise to connect laboratory systems, software and data infrastructure with AI-driven discovery workflows. Lab-in-the-loop – t...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admiss...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling first-in-human dataset from the nPulse Cardiac Catheter System created significant investigator interest within the EP community across the United States," said Vive...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie...

WASHINGTON--(BUSINESS WIRE)--Best Medical International (BMI), a TeamBest Global (TBG) company, celebrates its 50th anniversary this year, marking five decades of innovation, technological advancement, and a commitment to improving clinical outcomes and saving lives. After losing his father to colon cancer in 1968, Dr. Krishnan Suthanthiran founded BMI and as President, has dedicated his career to advancing cancer care and developing technologies and initiatives designed to improve the lives of...

ÉDIMBOURG, Écosse--(BUSINESS WIRE)--RoslinCT, l’un des principaux prestataires mondiaux de services de développement et de fabrication sous contrat (CDMO) dans le domaine des thérapies cellulaires, a annoncé aujourd’hui avoir obtenu une subvention de recherche et développement de la part de Scottish Enterprise afin d’accélérer la transformation numérique de ses opérations de fabrication en Écosse. Ce financement, soutenu par une subvention de R&D de Scottish Enterprise pouvant atteindre 7,2...

EDINBURGH, Schotland--(BUSINESS WIRE)--RoslinCT, een toonaangevende wereldwijde Contract Development and Manufacturing Organization (CDMO) op het gebied van celtherapie, heeft vandaag bekendgemaakt dat het een subsidie voor onderzoek en ontwikkeling heeft ontvangen van Scottish Enterprise om de digitale transformatie van zijn productieactiviteiten in Schotland te versnellen. De financiering wordt ondersteund door een R&D-subsidie van Scottish Enterprise ter waarde van maximaal 7,25 miljoen...

EDINBURGH, Schottland--(BUSINESS WIRE)--RoslinCT, ein weltweit führender Auftragsentwickler und -hersteller (CDMO) im Bereich Zelltherapie, gab heute bekannt, dass das Unternehmen von Scottish Enterprise einen Forschungs- und Entwicklungszuschuss erhalten hat, um die digitale Transformation seiner Fertigungsabläufe in Schottland voranzutreiben. Die Finanzierung, die durch einen F&E-Zuschuss von Scottish Enterprise in Höhe von bis zu 7,25 Millionen Pfund unterstützt wird, ist Teil des ehrgei...